Microbial Biomarkers for Hepatocellular Carcinoma

What is the Purpose of this Study?

This study focuses on patients who are about to begin treatment for advanced liver cancer at Cedars-Sinai. The purpose of the study is to determine how bacteria in the digestive tract could contribute to response to liver cancer treatment. The bacteria in the digestive tract help maintain a healthy immune system and may therefore affect how the body responds to treatments that target the immune system. Researchers will evaluate data in participants’ medical records; oral and stool samples will be collected to characterize bacteria in the digestive tract. The study aims to determine whether a biomarker test is helpful in predicting a patient’s response to liver cancer treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that may be a sign of a condition or disease.


Eligibility

Not Available


Where can I participate?

Cedars-Sinai Cancer at SOCC


What is the full name of this clinical trial?

Microbial Biomarkers for Hepatocellular Carcinoma

Study Details
Disease Type/Condition

Gastrointestinal Cancer, Liver Cancer

Principal Investigator

Gong, Jun

Co-Investigators

Andrew Hendifar

Age Group

Adult

Phase

N/A (Cancer Control)

IRB Number

STUDY00000280


How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Gastrointestinal Cancer, Liver Cancer

Principal Investigator

Gong, Jun

Age Group

Adult

Phase

N/A (Cancer Control)

IRB Number

EIIT2019-HUSSAIN-MICROBIO


Contact
Email
clinicaltrials@cshs.org